×

PEPTIDE VACCINE FOR INFLUENZA VIRUS

  • US 20100074920A1
  • Filed: 10/26/2007
  • Published: 03/25/2010
  • Est. Priority Date: 10/26/2006
  • Status: Abandoned Application
First Claim
Patent Images

1. A method for evaluating the potential of a chemical entity to bind to a peptide epitope derived from the divalent sialoside binding site of hemagglutinin protein of influenza virus comprising the steps of:

  • (i) contacting said chemical entity with said peptide under conditions that allow said chemical entity to bind said peptide; and

    (ii) detecting the presence of a complex of said chemical entity and said peptide;

    wherein said peptide epitope is peptide 1 corresponding to cysteine 97 region, and/or peptide 2 corresponding to cysteine 139 region and/or peptide 3 corresponding to the region of amino acids 220-226 as defined by the amino acid sequence of X31-hemaglutinin andwhereinsaid peptide epitope comprisesa) a conformational peptide epitope, comprising at least one cysteine residue or cysteine analogous amino acid residue conjugated from the side chain and the peptide epitope comprises less than 100 amino acid residues, preferably less than 30 amino acid residues present in a natural influenza virus peptide orb) the conformational peptide epitope is a short peptide epitope comprising 3 to 12 amino acid residues, preferably comprising less than 12 amino acid residues, more preferably less than 11 amino acid residue.

View all claims
  • 1 Assignment
Timeline View
Assignment View
    ×
    ×